11 July,2026 03:09 PM IST | New Delhi | mid-day online correspondent
Representational Image
The National Pharmaceutical Pricing Authority (NPPA) has fixed the retail prices of 39 new drug formulations under the provisions of the Drugs (Prices Control) Order (DPCO), 2013.
The notification, issued on July 8, covers medicines used to treat a range of medical conditions, including hypertension, diabetes, HIV, heart disease and eye infections. The move is aimed at ensuring that the prices of newly approved formulations remain regulated and affordable for patients.
Officials clarified that the notification is a retail price fixation order for new drug formulations under the DPCO, 2013, and should not be interpreted as a price reduction order for existing medicines.
Among the formulations covered under the notification, the retail price of Amlodipine + Bisoprolol + Telmisartan tablets, prescribed for the treatment of hypertension, has been fixed at Rs 14.74 per tablet.
The NPPA has also fixed the retail price of Nepafenac + Moxifloxacin Ophthalmic Solution, used after eye surgeries and for treating bacterial eye infections, at Rs 68.64 per ml.
Another formulation included in the notification is Clopidogrel + Aspirin + Atorvastatin capsules, commonly prescribed to reduce the risk of heart attacks and strokes. The retail price for the medicine has been fixed at Rs 6.37 per capsule.
The newly notified prices apply to the specified formulations and are intended to regulate their sale in the market under the provisions of the DPCO.
The NPPA reiterated that retailers and dealers must prominently display the latest price lists supplied by manufacturers at their business premises.
Quoting Paragraph 24(4) of the DPCO, 2013, the authority said, "As per para 24(4) of DPCO, 2013, every retailer and dealer shall display the price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same."
The authority said the requirement is intended to ensure transparency and allow consumers to verify the notified retail prices of medicines.
The NPPA also warned manufacturers and marketing companies against charging prices higher than those notified under the DPCO.
According to the notification, companies that fail to comply with the notified retail prices will be required to refund the excess amount collected from consumers along with applicable interest.
"In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955," the notification stated.
The NPPA regularly fixes retail prices for new drug formulations under the DPCO to regulate medicine prices and improve affordability while ensuring compliance with the country's pharmaceutical pricing framework.
